The National Pharmaceutical Council (NPC) recently sat down with the Society for Women’s Health Research (SWHR) Vice President of Public Policy Sarah Kocsis to discuss the society’s thinking on value assessments.
Kocsis also discussed what the society hopes to see during the Institute for Clinical and Economic Review’s (ICER) Jan. 23 meeting.
“Women comprise more than half of the U.S. population, and their diverse needs as patients, caregivers, and health care decision-makers must be captured in health care value assessments,” Kocsis said. “Women won’t benefit from new health care tools and therapies unless they can access them, so SWHR urges the unique burdens that many diseases have on women to be accounted for in determining the value of these innovations.”
To read the full discussion on NPC’s website, click here.